Galecto (Nasdaq:GLTO) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GLTO 주식 개요

는 임상 단계의 생명공학 회사로 섬유증, 암, 염증 및 기타 관련 질병의 치료를 위한 분자를 개발합니다.

GLTO 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

cash runway 경력이 1년 미만입니다.

수익은 향후 3년간 연평균 18.1% 씩 감소할 것으로 예상됩니다.

의미 있는 시가총액이 없습니다. ( $13M )

+ 2 더 많은 위험

Galecto, Inc. 경쟁사

Edesa Biotech

NasdaqCM:EDSA

US$13.7m

Alaunos Therapeutics

NasdaqCM:TCRT

US$10.0m

Nascent Biotech

OTCPK:NBIO

US$14.1m

Mainz Biomed

NasdaqCM:MYNZ

US$12.3m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Galecto
과거 주가
현재 주가	US$0.50
52주 최고치	US$3.70
52주 최저치	US$0.47
베타	1.23
11개월 변경	-19.43%
3개월 변경 사항	-36.54%
1년 변경 사항	-80.57%
33년 변화	-90.52%
5년 변화	n/a
IPO 이후 변화	-96.68%

최근 뉴스 및 업데이트

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Jan 10

Recent updates

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Oct 19

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19

Galecto GAAP EPS of -$0.67 beats by $0.02

Jul 29

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Jun 30

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Mar 10

Galecto: Selling At Cash Value

Dec 19

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Nov 18

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Jul 07

Galecto EPS misses by $0.07

May 04

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Mar 23

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Jan 29

Galecto EPS misses by $41.65

Dec 11

주주 수익률

	GLTO	US Biotechs	US 마켓
7D	-6.1%	-1.3%	0.4%
1Y	-80.6%	7.7%	22.9%

수익률 대 산업: GLTO 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: GLTO 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is GLTO's price volatile compared to industry and market?
GLTO volatility
GLTO Average Weekly Movement	7.7%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: GLTO 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: GLTO 의 주간 변동성은 지난 1년 동안 15% 에서 8% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2011	13	Hans Schambye	galecto.com

는 임상 단계의 생명공학 회사로 섬유증, 암, 염증 및 기타 관련 질병의 치료를 위한 분자를 개발합니다. 이 회사의 주요 제품 후보로는 골수섬유증 치료를 위한 임상 2a상 단계에 있는 GB2064가 있습니다. 또한 암 및 골수섬유증을 포함한 섬유성 질환 치료를 위한 임상 2a상 시험 중인 LOXL2의 선택적 경구용 저분자 억제제인 GB2064와 암 치료를 위한 임상 2a상 및 섬유증 치료를 위한 임상 Ib/IIa상 중인 선택적 경구용 갈렉틴-3 억제제인 GB1211을 개발하고 있습니다.

Galecto, Inc. 기본 사항 요약

Galecto 의 수익과 매출은 시가총액과 어떻게 비교하나요?
GLTO 기본 통계
시가총액	US$13.31m
수익(TTM)	-US$30.83m
수익(TTM)	n/a

0.0x

P/S 비율

-0.4x

P/E 비율

GLTO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
GLTO 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$30.83m
수익	-US$30.83m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.14
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

GLTO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

GLTO 주식 개요

보상

위험 분석

Galecto, Inc. 경쟁사

NasdaqCM:EDSA

US$13.7m

NasdaqCM:TCRT

US$10.0m

OTCPK:NBIO

US$14.1m

NasdaqCM:MYNZ

US$12.3m

가격 내역 및 성능

최근 뉴스 및 업데이트

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Galecto, Inc., Annual General Meeting, Jun 20, 2024

New major risk - Financial position

New minor risk - Share price stability

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Insufficient new directors

Recent updates

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Galecto, Inc., Annual General Meeting, Jun 20, 2024

New major risk - Financial position

New minor risk - Share price stability

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Insufficient new directors

Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis

Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial

Galecto Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Financial position

Price target increased by 17% to US$12.00

Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely

Price target increased by 18% to US$10.25

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

Price target decreased to US$8.33

High number of new and inexperienced directors

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022

Galecto, Inc’s Galectin-3 Inhibitor GB1211 to Be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc Announces Results from A Planned Intermediate Assessment of the Ongoing Phase 2A Trial of GB2064, a LOXL2 Inhibitor Product Candidate, for the Treatment of Myelofibrosis

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Price target decreased to US$10.00

Galecto GAAP EPS of -$0.67 beats by $0.02

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Enrolled in Phase 2 Trial of Gb1211 in Combination with Atezolizumab for First-Line Treatment of Nsclc

Price target decreased to US$11.00

High number of new directors

Galecto, Inc. Completes Enrollment in Global Phase 2B GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$9.50

Price target decreased to US$11.67

Galecto Publishes Results Showing Safety and Efficacy of the Gb0139 Inhaled Galectin-3 Inhibitor in Hospitalized Covid-19 Patients on Standard of Care

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Galecto: Selling At Cash Value

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor Gb1211 in Liver Cirrhosis

Galecto, Inc. Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor Gb2064 in Myelofibrosis (The MYLOX-1 Trial)

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc. Announces Preliminary Topline Results from Galectin-3 Inhibitor GB0139

Galecto EPS misses by $0.07

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Galecto, Inc. Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

New 90-day low: US$11.99

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Galecto, Inc. Announces the Appointment of Dr. Anne Prener to Its Board of Directors

Galecto EPS misses by $41.65

Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors

Galecto, Inc. has completed an IPO in the amount of $85.000005 million.

주주 수익률

가격 변동성

회사 소개